An autologous cell therapy based on our
T cell Antigen Coupler (TAC) platform.

Unlike conventional chimeric
receptors, our lead program co-opts
natural T cell biology and functions.

Unlike conventional chimeric receptors, our lead program co-opts natural T cell biology and functions.
T cell activation and signaling via the endogenous T cell receptor (TCR)

TAC100-HER2 is under development for targeting relapsed or refractory HER2-positive solid tumors.

Despite recent therapeutic advances in HER2 cancer research, there is still a significant unmet medical need. We are investigating TAC100-HER2 in multiple HER2-expressing tumors, including breast, gastric, gastroesophageal, and ovarian cancers.

HER2 Cancers

A novel and validated therapeutic target.

The amplification of human epidermal growth factor receptor 2 (HER2) is implicated as a major driver of tumor development and progression in several aggressive cancers. HER2-targeted therapies are frequently being tested in patients with solid tumors harboring HER2 overexpression.

However, cancers often develop resistance and stop responding to specific HER2-targeted therapies, creating a growing pool of patients who have progressed after prior anti-neoplastic therapies, including targeted agents. Our TAC technology has the potential to address that need, producing strong preclinical data in multiple models of HER2-overexpressing cancers.

Clinical Development

Emerging clinical
data supports
a differentiated
product profile.

TAC100-HER2

Interim results from the Phase I TACTIC-2 study demonstrated a favorable safety profile for TAC100-HER2 treatment, as well as early signals of clinical activity in patients with gastric and esophageal tumors, including impressive disease control rates and partial responses in heavily pre-treated patients. TAC100-HER2 is being investigated for the treatment of HER2-positive gastric and esophageal tumors in a Phase 2 trial, which is currently recruiting new patients.

A truly scalable technology for automating autologous cell therapy manufacturing.

Given the current challenges of existing autologous therapies, we have entered a risk-sharing collaboration with Lonza to use their Cocoon™ Manufacturing System. We believe the Cocoon will enable us to deliver a high-quality TAC100-HER2 cell therapy products for each patient in need.